1. Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers
Free full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2772668/
Fig 2: Valcyclovir reduced EBV+ B cell numbers [500mg/day for 1 year, n=45].
2. Relapsing EBV encephalitis in a renal transplant recipient
Free full text: https://pubmed.ncbi.nlm.nih.gov/29021960/
Fig 2: Valacycolvir reduced CSF EBV titers [800mg 5x/day for 2 weeks].
3. Axonal Polyneuropathy as an Unusual Manifestation of Acute Epstein-Barr Virus Infection in an Adult
Free full text: https://www.ima.org.il/FilesUploadPubli ... /98682.pdf
4. Antiviral treatment of a boy with EBV-associated hydroa vacciniforme
Free full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244348/
"During the treatment with oral antiviral drugs [valacyclovir at 500mg 2x/day] our patient has had fewer and milder skin eruptions."
5. Ataxia and Encephalitis in a Young Adult with EBV Mononucleosis: A Case Report [valacyclovir for 10 days]
Free full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3679774/
"Patient conducted home physical and speech therapy for 4–6 weeks. Initially, the patient was extremely worried about the possible permanence of any symptoms as she was well aware of her symptoms and their potential long-term impact on her personal and professional life. Processing speed was delayed, and patient was distressed upon learning she was reading at a 6th grade level. Patient was unable to type and had illegible handwriting. A formal neuropsychological evaluation was not conducted. With time and spiritual and emotional support, patient was able to regain resolve. Constitutional symptoms resolved soon after coming home, and sleep requirements recovered to baseline over the course of two weeks. Patient gradually regained functionality with IADLs with loss of ataxic symptoms. She was able to return to baseline by twelve weeks."
6. A virologic pilot study of valacyclovir in infectious mononucleosis
Abstract: https://pubmed.ncbi.nlm.nih.gov/17369082/
"Results: Twenty subjects were studied. The proportion of valacyclovir recipients [3g/day for 14 days, n=20] versus control subjects who had >or=2 log10 decrease in EBV copies was significantly greater for both oral wash fluid-derived cell pellet (P=0.03) and supernatant (P=0.001) samples. At the end of the treatment period, the number of reported symptoms (P=0.03) and the severity of illness (P=0.049) were reduced among valacyclovir recipients as compared with controls."
7. Valtrex therapy for Epstein-Barr virus reactivation and upper respiratory symptoms in elite runners
Abstract: https://pubmed.ncbi.nlm.nih.gov/15235312/
"Valtrex treatment [4 months, n=20] resulted in an 82% reduction in the detectable EBV load in saliva for EBV seropositive runners compared with the placebo treatment (P = 0.04)."